Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806334 · ClinicalTrials.gov registry record · NA
Radiogenomics of Muscle Invasive Bladder Cancer
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT04806334 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT04806334, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder cancer.
Interventions
- DIAGNOSTIC_TEST MRI imaging of the pelvis/bladder
- DIAGNOSTIC_TEST genomic analysis of tumor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2024-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04806334
The ClinicalTrials.gov registry entry for NCT04806334 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI imaging of the pelvis/bladder is the first listed.
NCT04806334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04806334 about?
NCT04806334 is a clinical study titled "Radiogenomics of Muscle Invasive Bladder Cancer". Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder cancer.
What is the current status of trial NCT04806334?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2021-03-02. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT04806334?
The interventions under investigation include: MRI imaging of the pelvis/bladder (DIAGNOSTIC_TEST), genomic analysis of tumor (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04806334?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.